Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04809103 | Intratumoral Cisplatin for Resectable NSCLC | PHASE1 | COMPLETED | 6 | — | — | Mar 8, 2021 | Oct 1, 2025 | Feb 6, 2026 | 1 | United States |
Adverse events as defined using the Common Terminology Criteria for Adverse Events
| Arm | Type | Description |
|---|---|---|
| Intratumoral Cisplatin 20 mg | EXPERIMENTAL | Second dose level |
| Intratumoral Cisplatin 10 mg | EXPERIMENTAL | First dose level |
| Name | Type | Description |
|---|---|---|
| cis-diamminedichloroplatinum | DRUG | Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC |
Inclusion Criteria: * Age ≥18 years. * Eastern Cooperative Oncology Group performance status 0 or 1 * Patients must have adequate organ and marrow function as defined below: * Leukocytes ≥3,000/microliter * Platelets ≥100,000/microliter * Total bilirubin ≤ institutional upper limit of normal...